Treatment or prophylaxis of thromboembolic disease in frail individuals with malignancy therefore requires a carefully tailored approach
Treatment or prophylaxis of thromboembolic disease in frail individuals with malignancy therefore requires a carefully tailored approach. or thromboembolism. Frailty in individuals with malignancy results from overlapping domains of ageing, Eastern Cooperative Oncology Group (ECOG) status, type of malignancy, poly-pharmacotherapy, cognitive impairment, blood disorders, and reduced life expectancy (Table 3). Table 3 Factors contributing to […]
Recent Comments